DBV Technologies Reports Q1 2026 Results and Plans H1 2026 BLA Submission for Viaskin Peanut Patch

DBV Technologies reported financial results for the first quarter ended March 31, 2026. The company ended the quarter with $229 million in cash and cash equivalents, providing a projected cash runway into the second quarter of 2027. This liquidity position was bolstered by $89 million in net proceeds from the full exercise of warrants issued in a March 2025 PIPE financing. Net loss for the quarter was $47.6 million, compared to $27.1 million in the prior year period, driven by increased R&D and SG&A expenses. The rise in spending reflects accelerated BLA-readiness activities and the build-out of U.S. commercial infrastructure. Operationally, DBV is focused on submitting its Biologics License Application (BLA) for the Viaskin Peanut patch in children aged 4-7 years in the first half of 2026, followed by a submission for toddlers aged 1-3 in the second half of 2026. The company also announced plans to initiate 'THRIVE,' a Phase 2 study evaluating Viaskin Peanut in infants aged 6-12 months. Clinical efforts remain ongoing for the COMFORT Toddlers study and VITESSE Open-label extension.